BioNTech SE
BNTX
$105.07
-$5.81-5.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.13B | 2.97B | 2.98B | 3.30B | 2.91B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.13B | 2.97B | 2.98B | 3.30B | 2.91B |
| Cost of Revenue | 631.14M | 608.79M | 584.76M | 518.02M | 497.44M |
| Gross Profit | 2.49B | 2.36B | 2.39B | 2.78B | 2.41B |
| SG&A Expenses | 589.12M | 631.01M | 648.05M | 660.43M | 662.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 341.02M | 652.17M | 698.51M | 193.20M | -152.88M |
| Total Operating Expenses | 3.95B | 4.33B | 4.37B | 3.78B | 3.35B |
| Operating Income | -823.97M | -1.36B | -1.39B | -475.90M | -441.84M |
| Income Before Tax | -430.21M | -840.49M | -731.97M | -339.05M | -266.01M |
| Income Tax Expenses | -48.29M | -27.86M | -14.84M | 161.73M | 277.75M |
| Earnings from Continuing Operations | -381.92 | -812.62 | -717.13 | -500.78 | -543.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -381.92M | -812.62M | -717.13M | -500.78M | -543.77M |
| EBIT | -823.97M | -1.36B | -1.39B | -475.90M | -441.84M |
| EBITDA | -544.53M | -1.09B | -1.12B | -295.63M | -265.43M |
| EPS Basic | -1.58 | -3.38 | -2.99 | -2.08 | -2.25 |
| Normalized Basic EPS | -0.78 | -1.86 | -1.58 | -0.60 | -0.51 |
| EPS Diluted | -1.60 | -3.40 | -3.00 | -2.11 | -2.28 |
| Normalized Diluted EPS | -0.78 | -1.86 | -1.59 | -0.62 | -0.53 |
| Average Basic Shares Outstanding | 963.84M | 962.63M | 962.81M | 962.27M | 960.39M |
| Average Diluted Shares Outstanding | 966.82M | 965.61M | 965.80M | 966.52M | 965.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |